
GlaxoSmithKline is set to sell the last of its Lucozade and Ribena assets, in Nigeria, to Suntory.
GlaxoSmithKline Nigeria's board of directors has accepted Suntory's offer to buy the remaining Lucozade Ribena business in the country.
GlaxoSmithKline is set to sell the last of its Lucozade and Ribena assets, in Nigeria, to Suntory.